AIRLINK 74.00 Decreased By ▼ -0.56 (-0.75%)
BOP 5.02 Decreased By ▼ -0.04 (-0.79%)
CNERGY 4.42 Decreased By ▼ -0.04 (-0.9%)
DFML 39.20 Decreased By ▼ -0.53 (-1.33%)
DGKC 86.09 Decreased By ▼ -1.46 (-1.67%)
FCCL 21.65 Decreased By ▼ -0.28 (-1.28%)
FFBL 34.01 Decreased By ▼ -0.58 (-1.68%)
FFL 9.92 Increased By ▲ 0.17 (1.74%)
GGL 10.56 Increased By ▲ 0.07 (0.67%)
HBL 113.89 Increased By ▲ 0.10 (0.09%)
HUBC 135.84 Decreased By ▼ -0.68 (-0.5%)
HUMNL 11.90 Increased By ▲ 1.00 (9.17%)
KEL 4.84 Increased By ▲ 0.17 (3.64%)
KOSM 4.53 Decreased By ▼ -0.11 (-2.37%)
MLCF 38.27 Decreased By ▼ -0.19 (-0.49%)
OGDC 134.85 Decreased By ▼ -1.29 (-0.95%)
PAEL 26.35 Decreased By ▼ -0.26 (-0.98%)
PIAA 20.80 Decreased By ▼ -1.69 (-7.51%)
PIBTL 6.68 Increased By ▲ 0.01 (0.15%)
PPL 123.00 Increased By ▲ 0.71 (0.58%)
PRL 26.69 Decreased By ▼ -0.28 (-1.04%)
PTC 14.33 Increased By ▲ 0.42 (3.02%)
SEARL 59.12 Decreased By ▼ -0.75 (-1.25%)
SNGP 69.50 Decreased By ▼ -0.56 (-0.8%)
SSGC 10.33 Decreased By ▼ -0.02 (-0.19%)
TELE 8.50 Decreased By ▼ -0.04 (-0.47%)
TPLP 11.23 Decreased By ▼ -0.11 (-0.97%)
TRG 64.85 Decreased By ▼ -1.15 (-1.74%)
UNITY 26.25 Decreased By ▼ -0.08 (-0.3%)
WTL 1.34 Decreased By ▼ -0.01 (-0.74%)
BR100 7,851 Increased By 26.3 (0.34%)
BR30 25,337 Decreased By -69.2 (-0.27%)
KSE100 75,207 Increased By 122.8 (0.16%)
KSE30 24,143 Increased By 49.1 (0.2%)

GENEVA: The World Health Organization said Tuesday it is no longer recommending additional Covid-19 vaccine booster doses for regular, medium-risk adults as the benefit was marginal.

For such people who have received their primary vaccination course and one booster dose, there is no risk in having further jabs but the returns are slight, the WHO’s vaccine experts said.

The UN health agency’s Strategic Advisory Group of Experts on Immunisation (SAGE) issued updated recommendations after its regular biannual meeting.

SAGE’s new advice reflects the impact of the dominant Omicron variant of the virus and high-level immunity now achieved in the population through infection and vaccination, the WHO said.

SAGE came up with three new, simplified priority categories for Covid vaccination: high, medium and low, based on risk of severe disease or death.

SAGE recommended additional booster shots after the first one only for people at the highest risk of developing severe Covid-19 disease.

They include older adults; younger adults with comorbidities such as diabetes, people with immunocompromising conditions like HIV, pregnant women, and frontline health workers.

The medium priority group includes healthy adults, usually under 60, and children and adolescents with comorbidities.

SAGE recomends a primary series and a first booster dose.

“When it comes to the medium-risk group, additional booster doses... are no longer recommended,” said SAGE chair Hanna Nohynek.

“The vaccine is safe and it’s efficient against serious disease and death,” she said, but for this risk group, while there was no harm in having another shot, “the benefit of these additional boosters is actually quite marginal”.

The low priority group includes healthy children and adolescents aged six months to 17 years.

While primary and booster doses are safe and effective for this group, considering the low burden of Covid disease, SAGE said countries’ vaccination decisions should be based “on contextual factors” such as health programme priorities and cost effectiveness.

As for the impact of Covid-19 vaccines on Long Covid, or post-infection conditions, “the evidence on the extent of their impact is inconsistent”, said SAGE.

Nearly 13.3 billion Covid vaccine doses have been administered around the world.

WHO vaccines chief Kate O’Brien said that versus Omicron, the existing vaccines provide very good immunity against severe disease, but “frankly they don’t last very long for the performance that they do have against mild disease or infection”.

The WHO is looking for new Covid vaccines that cover a broad spectrum of variants, have longer durability and better performance against infection and transmission.

It is also seeking vaccines that are move on from injection methods and ultra cold chain storage, O’Brien said, citing nasal, oral and skin patch vaccine methods.

Comments

Comments are closed.